Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease

INTRODUCTION: The negative efficacy study examining the γ-secretase inhibitor semagacestat in mild to moderate Alzheimer’s disease (AD) included a number of biomarkers of the disease as well as safety outcomes. We analyzed these data to explore relationships between drug exposure and pharmacodynamic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Alzheimers Res Ther
Main Authors: Doody, Rachelle S, Raman, Rema, Sperling, Reisa A, Seimers, Eric, Sethuraman, Gopalan, Mohs, Richard, Farlow, Martin, Iwatsubo, Takeshi, Vellas, Bruno, Sun, Xiaoying, Ernstrom, Karin, Thomas, Ronald G, Aisen, Paul S
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4461930/
https://ncbi.nlm.nih.gov/pubmed/26064192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-015-0121-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados